Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Phase III Study With OncoVEX (GM-CSF) in Head and Neck Cancer
Date:9/15/2009

ession is responsible for the majority of deaths. The two year loco-regional failure rate following front line treatment is around 30% with a further 20% of patients progressing at a distant site. The long-term loco-regional control rate of 100% combined with the high percentage of patients that remain disease free at up to 40 months from treatment is very encouraging and provides confidence that OncoVEX (GM-CSF) will significantly reduce relapse rates as compared to standard therapy alone in the pivotal study recently agreed with the FDA."

About Head and Neck Cancer

Head and neck cancer accounts for 47,000 new cases (3% of all new cancer cases and 2% of all cancer deaths) in the United States annually; it is the fifth most common malignancy worldwide (an estimated 644,000 new cases annually).

Patients with locally advanced tumors are best treated with concurrent chemoradiation, with planned neck dissection indicated in certain patients. Despite aggressive treatment of locally advanced disease loco-regional recurrences develop in 30% of patients and distant metastases in 20%. Aggressive combined modality therapy may be frequently associated with debility, and numerous physical and psychological symptoms including pain, dysphagia, weight loss, disfigurement, depression, and xerostomia (dry mouth). As a result, new and improved, and less toxic therapies for head and neck cancer are urgently required.

About BioVex

BioVex is a privately held biotechnology company based in Woburn, MA where it also has an operational launch grade manufacturing facility. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX (GM-CSF) is a first-in-class oncolytic, or cancer destroying virus technology. OncoVEX (GM-CSF) designed to work by; repli
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
2. BioVex Raises $40 Million in First Close of Series F Financing
3. BioVex to Present at the UBS Global Life Sciences Conference
4. BioVex Closes Second Round of Series E Financing
5. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
6. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
7. CardioDynamics Agrees to be Acquired by SonoSite for $1.35 Per Share
8. MannKind Agrees with Pfizer on the Purchase of Frankfurt Insulin Manufacturing Plant
9. PharmaNet Development Group Agrees to be Acquired by JLL Partners
10. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 21, 2015 Cambridge Semantics, the leading provider ... announced that 2014 was a record-breaking year across the board ... the Anzo Smart Data Platform and our Smart Data solutions, ... from diverse data which led to record growth for the ...
(Date:1/22/2015)... California (PRWEB) January 22, 2015 Pipette.com ... Offer to their comprehensive portfolio of Eppendorf products. ... customers to purchase a Centrifuge 5424/5424 R and receive ... of either Eppendorf Research plus or Eppendorf Reference 2 ...
(Date:1/22/2015)... Geneva, Switzerland (PRWEB) January 22, 2015 ... for characterized mammalian Research Cell Banks (RCBs) used for ... generated Research Cell Banks will include Next-Generation Sequencing ... cell’s genetic architecture de-risks biologic manufacturing by ensuring the ...
(Date:1/22/2015)... Jan. 22. 2015  Varian Medical Systems (NYSE: VAR ... honored for its commitment to sustainability with inclusion on a ... the highest ranked healthcare equipment company among the Corporate Knights ... World Economic Forum at Davos, Switzerland . ...
Breaking Biology Technology:Cambridge Semantics Announces Record Results for 2014 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Varian Honored Among World's 100 Most Sustainable Corporations 2
... Acquisition Adds Late Stage Product Targeting Life-threatening Hereditary ... - Company to Host Conference Call at 10:30 A.M. Eastern Today ... ... 15 ViroPharma Incorporated,(Nasdaq: VPHM ) and Lev Pharmaceuticals, Inc. (OTC ...
... Inc. (OTC Bulletin Board: CHBT) ("China-Biotics," "the,Company"), ... manufacture,research, development, marketing and distribution of probiotics ... Transfer & Trust Company,("AST") as its new ... 2008.,AST, headquartered in New York, New York, ...
... CryoLife, Inc. (NYSE: CRY ),a biomaterials, medical ... 2008 financial results will be released on,Thursday, July 31, ... webcast at 10:00 a.m. Eastern Time, July 31, 2008, ... session hosted by Steven G.,Anderson, president and CEO of ...
Cached Biology Technology:ViroPharma To Acquire Lev Pharmaceuticals 2ViroPharma To Acquire Lev Pharmaceuticals 3ViroPharma To Acquire Lev Pharmaceuticals 4ViroPharma To Acquire Lev Pharmaceuticals 5ViroPharma To Acquire Lev Pharmaceuticals 6ViroPharma To Acquire Lev Pharmaceuticals 7ViroPharma To Acquire Lev Pharmaceuticals 8ViroPharma To Acquire Lev Pharmaceuticals 9China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008 2CryoLife Announces Release Date and Teleconference Call Details for Second Quarter 2008 Financial Results 2
(Date:12/17/2014)... , Dec. 15, 2014  HITLAB SM announced today ... to confirm its adherence to current U.S. Food and ... conduct regulated smart device and smart phone application trials ... quality. "HITLAB is determined to improve global ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this market is ... Chemical sensors help in recording of patient data for ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Global Facial Recognition Market 2015-2019" report ... Facial recognition is a technology used ... the overall facial feature of a person such as ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Commemorate JPMorgan Chase & Co. , Foundation Funding of ... , , ... Franklin McKinley School District and Bring Me A Book (BMAB) ... San Jose Elementary School Library Initiative in Franklin McKinley School District.  The ...
... the University of California, Riverside Norman Ellstrand ... been awarded 2010 Guggenheim Fellowships by the John ... appointed on the basis of achievement and exceptional promise. ... genetics, genomics, and the many faces of hybridization. Herrera, ...
... The U.S. Environmental Protection Agency today awarded more than ... the country who participated in the 6th Annual National ... D.C. The P3 award competition and National Sustainable ... of Earth Day, April 23-26. Winners of the EPA,s ...
Cached Biology News:JPMorgan Chase & Co., Invests $25,000 to Support Bring Me A Book's San Jose Elementary School Library Initiative 2JPMorgan Chase & Co., Invests $25,000 to Support Bring Me A Book's San Jose Elementary School Library Initiative 32 professors at UC Riverside receive Guggenheim Fellowships 22 professors at UC Riverside receive Guggenheim Fellowships 3EPA awards more than $1 million to college teams for environmental innovation 2
VEGF Receptor-2, phospho-specific (Tyr996)...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
Biology Products: